stockrowDefinium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Free cash flow margin
Definium Therapeutics, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2025) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 11.7% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. compare | 0.00% |
| DFTX Definium Therapeutics, Inc. | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −9.58% |
| IOVA Iovance Biotherapeutics, Inc. compare | −57.0% |
| ABCL AbCellera Biologics Inc. compare | −180.8% |
| RLAY Relay Therapeutics, Inc. compare | −1,924.6% |
| DNTH Dianthus Therapeutics, Inc. compare | −6,469.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue